Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
[size=1em]
[size=1.5]- http://orcid.org/0000-0001-5525-0267[size=1.7]Edoardo Caronna[size=1.2]1[size=1.2],[size=1.2]2,
- [size=1.7]Victor Jos¨¦ Gallardo[size=1.2]2,
- [size=1.7]Gabriella Egeo[size=1.2]3,
- [size=1.7]Manuel Mill¨¢n V¨¢zquez[size=1.2]4,
- [size=1.7]Candela Nieves Castellanos[size=1.2]5,
- [size=1.7]Javier A Membrilla[size=1.2]6[size=1.2],[size=1.2]7,
- [size=1.7]Gloria Vaghi[size=1.2]8[size=1.2],[size=1.2]9,
- [size=1.7]Joana Rodr¨ªguez-Montolio[size=1.2]10[size=1.2],[size=1.2]11,
- [size=1.7]Neus Fabregat Fabra[size=1.2]12,
- [size=1.7]Francisco S¨¢nchez-Caballero[size=1.2]13,
- [size=1.7]Alex Jaimes S¨¢nchez[size=1.2]14,
- [size=1.7]Albert Muñoz-Vendrell[size=1.2]15,
- [size=1.7]Renato Oliveira[size=1.2]16,
- [size=1.7]Gabriel G¨¢rate[size=1.2]17,
- [size=1.7]Y¨¦sica Gonz¨¢lez-Osorio[size=1.2]18,
- [size=1.7]Daniel Guisado-Alonso[size=1.2]19,
- [size=1.7]Raffaele Ornello[size=1.2]20,
- [size=1.7]Cem Thunstedt[size=1.2]21,
- [size=1.7]Iris Fern¨¢ndez-L¨¢zaro[size=1.2]22,
- [size=1.7]Marta Torres-Ferr¨²s[size=1.2]1[size=1.2],[size=1.2]2,
- [size=1.7]Alicia Alpuente[size=1.2]1[size=1.2],[size=1.2]2,
- [size=1.7]Paola Torelli[size=1.2]23,
- [size=1.7]Cinzia Aurilia[size=1.2]3,
- [size=1.7]Raquel Lamas P¨¦re[size=1.2]4,
- [size=1.7]Maria Jos¨¦ Ruiz Castrillo[size=1.2]6,
- [size=1.7]Roberto De Icco[size=1.2]8[size=1.2],[size=1.2]9,
- [size=1.7]Grazia Sances[size=1.2]9,
- [size=1.7]Sarah Broadhurst[size=1.2]24,
- [size=1.7]Hui Ching Ong[size=1.2]24,
- [size=1.7]Andrea G¨®mez Garc¨ªa[size=1.2]14,
- [size=1.7]Sergio Campoy[size=1.2]15[size=1.2],[size=1.2]25,
- [size=1.7]Jordi Sanahuja[size=1.2]26,
- [size=1.7]Gonçalo Cabral[size=1.2]27,
- [size=1.7]Isabel Beltr¨¢n Blasco[size=1.2]28,
- [size=1.7]Marta Waliszewska-Pros¨®ł[size=1.2]29,
- [size=1.7]Liliana Pereira[size=1.2]30,
- [size=1.7]Almudena Layos-Romero[size=1.2]31,
- [size=1.7]Isabel Luzeiro[size=1.2]32[size=1.2],[size=1.2]33,
- [size=1.7]Laura Dorado[size=1.2]34,
- [size=1.7]Mar¨ªa Rocio Álvarez Escudero[size=1.2]35,
- [size=1.7]Arne May[size=1.2]36,
- [size=1.7]Alba L¨®pez-Bravo[size=1.2]11[size=1.2],[size=1.2]37,
- [size=1.7]Isabel Pavão Martins[size=1.2]38,
- [size=1.7]Christina Sundal[size=1.2]39[size=1.2],[size=1.2]40[size=1.2],[size=1.2]41[size=1.2],[size=1.2]42,
- [size=1.7]Pablo Irimia[size=1.2]43,
- [size=1.7]Alberto Lozano Ros[size=1.2]44,
- [size=1.7]Ana Beatriz Gago-Veiga[size=1.2]22,
- [size=1.7]Fernando Velasco Juanes[size=1.2]45,
- [size=1.7]Ruth Ruscheweyh[size=1.2]21,
- [size=1.7]Simona Sacco[size=1.2]20,
- [size=1.7]Elisa Cuadrado-Godia[size=1.2]19[size=1.2],[size=1.2]46,
- http://orcid.org/0000-0002-3132-1064[size=1.7]David Garc¨ªa-Azor¨ªn[size=1.2]18,
- [size=1.7]Julio Pascual[size=1.2]17,
- [size=1.7]Raquel Gil-Gouveia[size=1.2]16[size=1.2],[size=1.2]47,
- [size=1.7]Mariano Huerta-Villanueva[size=1.2]15[size=1.2],[size=1.2]25,
- [size=1.7]Jaime Rodriguez-Vico[size=1.2]14,
- [size=1.7]Javier Viguera Romero[size=1.2]13,
- [size=1.7]Victor Obach[size=1.2]12,
- [size=1.7]Sonia Santos-Lasaosa[size=1.2]10[size=1.2],[size=1.2]11,
- [size=1.7]Mona Ghadiri-Sani[size=1.2]24,
- [size=1.7]Cristina Tassorelli[size=1.2]8[size=1.2],[size=1.2]9,
- [size=1.7]Javier D¨ªaz-de-Ter¨¢n[size=1.2]6[size=1.2],[size=1.2]7,
- [size=1.7]Samuel D¨ªaz Insa[size=1.2]5,
- [size=1.7]Carmen Gonz¨¢lez Oria[size=1.2]4,
- [size=1.7]Piero Barbanti[size=1.2]3[size=1.2],[size=1.2]48,
- http://orcid.org/0000-0003-0796-4702[size=1.7]Patricia Pozo-Rosich[size=1.2]1[size=1.2],[size=1.2]2
- For the EUREkA study group
- Correspondence to Dr Patricia Pozo-Rosich, Neurology Department, Vall d¡¯Hebron Hospital, Barcelona, Spain; [email protected]
Cite this article as:Caronna E, Gallardo VJ, Egeo G, et al
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
Journal of Neurology, Neurosurgery & Psychiatry Published Online First: 22 May 2024.
doi: 10.1136/jnnp-2023-333295
|